BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

December 14, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced that the squamous histology non-small cell lung cancer (NSCLC) cohort of the phase 2 iNSITE 1 trial will advance to the second stage and complete enrollment to 40 patients. The company also announced that the KRAS mutant NSCLC arm will not advance to the second stage.

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

December 15, 2015

CAMBRIDGE, Mass., December 15, 2015 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics (TM), announced today that Elizabeth (Betsy) Nabel, M.D., President of Harvard-affiliated Brigham and Women's Health Care (BWHC) has been appointed to the company's Board of Directors.

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

December 11, 2015

BUSINESS WIRE--Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS). The Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

December 11, 2015

CAMBRIDGE, Mass., Dec. 6, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced new data from the dose-escalation phase and expansion cohorts from the ongoing Phase 1/2 study evaluating single agent AG-221, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (IDH2), in advanced hematologic malignancies.

EcoSense Lighting Acquires Journee Lighting

EcoSense Lighting Acquires Journee Lighting

December 11, 2015

LOS ANGELES, Dec. 8, 2015 /PRNewswire/ -- EcoSense®, a fast-growing LED technology company, announced today that it has acquired the assets of Journée Lighting. Journée Lighting is a privately owned, CA-based lighting company that specializes in the design and development of specification grade lighting.

Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics™

Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics™

December 9, 2015

Following 18 Months of Technology Development, Company Advances Breakthrough Therapeutic Platform with $25M of Initial Capital

ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences

ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences

November 17, 2015

 Company Secures $80+ Million in Committed Funding to Develop Exosome-Based Therapeutic and Diagnostic Products

Joule and Red Rock Biofuels Announce Intent to Merge, Creating an Industry-Leading Carbon-Neutral Fuel Production Platform

Joule and Red Rock Biofuels Announce Intent to Merge, Creating an Industry-Leading Carbon-Neutral Fuel Production Platform

November 12, 2015

Dr. Brian Baynes Named CEO Replacing Serge Tchuruk Who Will Continue in Board Role

BEDFORD, Mass. & FT. COLLINS, Colo.--(BUSINESS WIRE)--Joule, the pioneer of liquid fuels from recycled CO2, and Red Rock Biofuels, a leading developer of renewable jet and diesel fuel bio-refineries, today announced their intent to merge. Red Rock adds a proven technology pathway to Joule’s own Helioculture technology and strengthens Joule’s platform for global supply of carbon neutral fuels. The transaction is expected to close during the coming 30 days.

Syros Pharmaceuticals Announces Issuance of U.S. Patents Related to Its Gene Control Drug Discovery and Development Platform

Syros Pharmaceuticals Announces Issuance of U.S. Patents Related to Its Gene Control Drug Discovery and Development Platform

November 10, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced that the U.S. Patent and Trademark Office issued two patents related to the Company’s proprietary gene control platform for mapping and drugging crucial genes that become dysregulated in disease. The covered inventions include methods for identifying specialized regions of DNA, known as super-enhancers, which are part of the foundation of the Company’s drug discovery and development platform.

Seres Therapeutics Appoints Kurt Graves to Board of Directors

Seres Therapeutics Appoints Kurt Graves to Board of Directors

November 10, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2015-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced the appointment of Kurt Graves to the company’s board of directors. Mr. Graves, the Chairman, President and CEO of Intarcia Therapeutics, is an industry leader who brings to Seres extensive experience from his 25-year career at top-tier pharmaceutical and biotech companies.